All feline diagnoses

Your cat was diagnosed with Nasal Lymphoma. One of the more treatable feline lymphomas with longest survival data. Presents with nasal discharge, facial deformity, epistaxis. Compare 9 treatment options for cats including Radiation Therapy (Definitive), Stereotactic Radiation Therapy (SRT/SBRT), Radiation + Chemotherapy (Combined Modality) — with survival times, costs, and what to expect during treatment.

🐈

Nasal Lymphoma

nasal/extranodal

feline

Round Cell

About This Cancer

Nasal lymphoma in cats is one of the more treatable forms of feline lymphoma. The cancer develops in the nasal cavity, often from B-lymphocytes, and causes progressive nasal obstruction, discharge (frequently bloody), snoring or noisy breathing, and sometimes facial deformity as the tumour expands within the nasal passages. Unlike many other cancers that originate in the nose, feline nasal lymphoma responds very well to radiation therapy, and cats can achieve long-lasting remission with appropriate treatment. The outlook is significantly better than for most other forms of feline lymphoma, with some cats surviving two to three years or more. A critical prognostic factor is whether the tumour has eroded through the cribriform plate into the brain — this represents a more advanced and less favourable stage of disease.

WHO Modified Staging for Feline Lymphoma

Standard staging. Nasal lymphoma is typically Stage I (single extranodal site) at presentation.

Stage ISingle tumour (extranodal) or single anatomic area (nodal)
Stage IITwo or more tumours on same side of diaphragm
Stage IIITumours on both sides of diaphragm
Stage IVLiver and/or spleen involvement
Stage VBone marrow or blood involvement
Prognostic Factors(4)
Cribriform plate destructionDestruction before therapy is a negative prognostic indicator(Haney et al., 2009)
Complete response achievementBest single prognostic factor — CR significantly improves survival(Haney et al., 2009)
RT doseTotal RT dose >32 Gy associated with better outcomes(Haney et al., 2009)
Anaemia at presentationNegative prognostic factor(Haney et al., 2009)
Minimum Workup(8 steps)
1CRITICAL WARNING: Avoid administering prednisolone/prednisone BEFORE obtaining biopsy/cytology — corticosteroids can induce multi-drug resistance (MDR) and cause rapid tumour lysis, making subsequent histopathological diagnosis difficult or impossible. Complete diagnostic workup BEFORE starting any corticosteroid therapy.
2CBC, comprehensive chemistry panel
3FeLV/FIV testing
4Nasal CT or MRI (assess extent, cribriform plate integrity)
5Nasal biopsy with histopathology and immunophenotyping
6Thoracic radiographs (staging)
7Abdominal ultrasound (staging)
8Rhinoscopy if available

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Radiation Therapy (Definitive)
~20 mo (15–30)
Stereotactic Radiation Therapy (SRT/SBRT)
~12 mo
Radiation + Chemotherapy (Combined Modality)
~31 mo (6–31)
Chemotherapy Alone (COP/CHOP)
~8 mo (4–12)
Prednisolone Alone (Palliative)
~2 mo (1–3)
Rescue/Relapse Guidance
See notes
Lomustine (CCNU) Rescue
See notes
Single-Agent Doxorubicin Rescue
See notes
Protocol Switch (COP↔CHOP)
See notes
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.